Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

BACKGROUND: Patients with RAS wild‐type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti‐epidermal growth factor receptor (EGFR) combined with first‐line, 5‐fluorouracil‐based chemotherapy. Without the RAS status information, the oncologist can either...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Palmieri, Lola‐Jade, Mineur, Laurent, Tougeron, David, Rousseau, Benoît, Granger, Victoire, Gornet, Jean‐Marc, Smith, Denis, Lievre, Astrid, Galais, Marie‐Pierre, Doat, Solene, Pernot, Simon, Bignon‐Bretagne, Anne‐Laure, Metges, Jean‐Philippe, Baba‐Hamed, Nabil, Michel, Pierre, Obled, Stéphane, Vitellius, Carole, Bouche, Olivier, Saban‐Roche, Léa, Buecher, Bruno, des Guetz, Gaëtan, Locher, Christophe, Trouilloud, Isabelle, Goujon, Gaël, Dior, Marie, Manfredi, Sylvain, Soularue, Emilie, Phelip, Jean‐Marc, Henriques, Julie, Vernery, Dewi, Coriat, Romain
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Gastrointestinal Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7011620/
https://ncbi.nlm.nih.gov/pubmed/32043796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0328
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars